Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -534.27% is 46% above its 5-year average of -996.69%, near the high end of its 5-year range (-2115.08%–77.35%).
22.59% above its 12-month average of -690.15%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -1346.81%.
NET PROFIT MARGIN
-534.27%
NET PROFIT MARGIN AVG TTM
-690.15%
NET PROFIT MARGIN AVG 3Y
-1160.39%
NET PROFIT MARGIN AVG 5Y
-996.69%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+22.59%
CURRENT VS 3Y AVG
+53.96%
CURRENT VS 5Y AVG
+46.40%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 787 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Femasys Inc.
Market Cap
$6.28M
Net Profit Margin
-534.27%
TTM Avg
-690.15%
3Y Avg
-1160.39%
5Y Avg
-996.69%
Market Cap
$6.46M
Net Profit Margin
-1084.23%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$5.93M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-86.55%
Market Cap
$6.53M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$6.54M
Net Profit Margin
-84.79%
TTM Avg
-89.20%
3Y Avg
-105.63%
5Y Avg
-91.66%
Market Cap
$5.98M
Net Profit Margin
-44771.83%
TTM Avg
-33930.36%
3Y Avg
-151894.64%
5Y Avg
-112740.11%
Market Cap
$5.92M
Net Profit Margin
-4620.92%
TTM Avg
-1491.69%
3Y Avg
-1081.40%
5Y Avg
-732.36%
Market Cap
$6.88M
Net Profit Margin
-6523.04%
TTM Avg
-4247.49%
3Y Avg
-2263.82%
5Y Avg
-1493.48%
Market Cap
$5.82M
Net Profit Margin
-225.28%
TTM Avg
-379.90%
3Y Avg
-549.78%
5Y Avg
-669.44%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Femasys Inc. (FEMY) | $6.28M | -534.27% | -690.15% | -1160.39% | -996.69% |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.46M | -1084.23% | 0.00% | 0.00% | 0.00% |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $5.93M | 0.00% | 0.00% | 0.00% | -86.55% |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.53M | 0.00% | 0.00% | 0.00% | 0.00% |
| Biomerica, Inc. (BMRA)vs › | $6.54M | -84.79% | -89.20% | -105.63% | -91.66% |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $5.98M | -44771.83% | -33930.36% | -151894.64% | -112740.11% |
| Scienture Holdings, Inc. (SCNX)vs › | $5.92M | -4620.92% | -1491.69% | -1081.40% | -732.36% |
| Co-Diagnostics, Inc. (CODX)vs › | $6.88M | -6523.04% | -4247.49% | -2263.82% | -1493.48% |
| Lucyd, Inc (LUCY)vs › | $5.82M | -225.28% | -379.90% | -549.78% | -669.44% |
| Aclarion, Inc. (ACON)vs › | $6.72M | -10978.48% | -12422.83% | -10763.38% | -10131.90% |
Operating Margin
-763.9%
Net Profit Margin
-534.3%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -1346.81% |
| 2026-03-31 | 77.35% |
| 2025-12-31 | -485.66% |
| 2025-09-30 | -575.11% |
| 2025-06-30 | -1120.52% |
| 2025-03-31 | -1727.94% |
| 2024-12-31 | -881.00% |
| 2024-09-30 | -974.73% |
| 2024-06-30 | -2115.08% |
| 2024-03-31 | -1327.55% |
| 2023-12-31 | -2069.56% |
| 2023-09-30 | -1635.66% |
| 2023-06-30 | -902.77% |
| 2023-03-31 | -1002.18% |
| 2022-12-31 | -1235.55% |
| 2022-09-30 | -858.48% |
| 2022-06-30 | -869.02% |
| 2022-03-31 | -897.10% |
| 2021-12-31 | -929.85% |
| 2021-09-30 | -838.23% |
| 2021-06-30 | -332.22% |
| 2021-03-31 | -554.99% |
| 2020-12-31 | -590.65% |
| 2020-09-30 | -500.72% |
| 2020-06-30 | -810.69% |
| 2020-03-31 | -845.15% |
